anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Autism is traditionally diagnosed behaviorally but has a strong genetic basis. A genetics-first approach could transform understanding and treatment of autism. However, isolating the gene-brain-behavior relationship from confounding sources of variability is a challenge. We demonstrate a novel technique, 3D transport-based morphometry (TBM), to extract the structural brain changes linked to genetic copy number variation (CNV) at the 16p11.2 region. We identified two distinct endophenotypes. In data from the Simons Variation in Individuals Project, detection of these endophenotypes enabled 89 to 95% test accuracy in predicting 16p11.2 CNV from brain images alone. Then, TBM enabled direct visualization of the endophenotypes driving accurate prediction, revealing dose-dependent brain changes among deletion and duplication carriers. These endophenotypes are sensitive to articulation disorders and explain a portion of the intelligence quotient variability. Genetic stratification combined with TBM could reveal new brain endophenotypes in many neurodevelopmental disorders, accelerating precision medicine, and understanding of human neurodiversity.
The invention consists of peptides which inhibit the secretion of neurotransmitters from synaptic vesicles. The peptides of the invention are believed to mimic the activity of neurotoxins produced by Clostridium botulinum and tetani (including botulinum serotypes A, B, C, D, E, F and G). Structurally, the peptides are comprised of amino acid fragments from the substrate binding domains selected from three proteins which bind to form a receptor for docking of synaptic vesicles to the plasma membranes of neuronal cells; i.e., SNAP-25, VAMP-2 and syntaxin. Certain of the inventive peptides exhibit strong inhibitory activity; e.g. 50 % or greater decline in neurotransmitter release is obtained at even nanomolar concentrations. The peptides are suited for use as substitutes for Clostridium neurotoxins in clinical applications and in compounds for targeted delivery of drugs into neural cells.
The experimental study was conducted on a medical center of North Taiwan. 66 patients with Tuberculosis were included in this study. Patients who fit the inclusion criteria were randomly assigned to either experimental or control group. Patients in experimental group could choose a piece of CD and listen to music with earphone for 30 minutes. Patients in control group just rest for 30 minutes. The procedure was implemented once a day, and sustained for total 5 days.
Disclosed herein is an antibacterial cleansing composition. The cleansing composition is free of triclosan and comprises lactic acid/lactate, at least one C2 to C3 alcohol, and glutamate diacetate. Lactic acid/lactate is present in the composition in an amount of about 5 weight percent (wt %) to about 15 wt %, based on the total weight of the composition. The C2 to C3 alcohol is present in an amount of about 1 wt % to about 20 wt %, based on the total weight of the composition. Glutamate diacetate is present in an amount of about 0.05 wt % to about 5 wt %. The pH of the composition is about 4 to about 5. The triclosan-free cleansing composition according to the invention has superior antibacterial activity that surpasses comparable triclosan-free formulations that do not contain glutamate diacetate.
Isolated splenic peliosis is an extremely rare condition characterized by the presence of multiple blood-filled cavities, occasionally resulting in non-traumatic splenic rupture with fatal bleeding. In our case, a 64-year-old man was brought by ambulance due to weakness and abdominal pain without nausea or febrility. On clinical examination, the patient was sensitive to palpation with significant tenderness over the abdomen but no associated features of peritonitis. He collapsed during the imaging examination and became unconscious and asystolic. Cardiopulmonary resuscitation was not successful. The patient died approximately within 2 hours of admission to the hospital. Postmortal examination showed 2800 ml of intraperitoneal blood with clots and a laceration of the lower pole of the spleen. Macroscopic examination of the spleen revealed huge nodular splenomegaly, measuring 21 cm x 19 cm x 5 cm, weighing 755 g. On the cut surfaces, multiple randomly distributed blood-filled cavities ranging from 0,5 to 2 cm in diameter were seen. At microscopic examination, the specimens showed multiple irregular haemorrhagic cyst-like lesions that were not lined by any epithelium or sinusoidal endothelium, consistent with the diagnosis of peliosis lienis. Although the condition is often clinically silent, the forensic pathological significance arises from the differential diagnosis of resultant intraperitoneal haemorrhage and sudden death, mimicking a violent death.
Method The adults whose age between 20\~65 years old, BMI between 27kg/m² and 35kg/m², and also have snoring during sleeping are able to be enrolled in the study. Then, the general data questionnaire, Body Constitution Questionnaire, physical examination, blood test, and genetic test are provided to subjects. The blood test includes High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin; the DNA test includes FTO、MC4R、BDNF、PPARG、ADRB3、UCP1. Epworth Sleepiness Scale, laryngoscope and polysomnography are also performed in the patients enrolled. The Traditional Chinese medicine constitution can be classified and its relationship between different figure types, serum lipid level as well as obesity-related gene can be analyzed. The results will be described after a statistical analysis.

Aim The aim of this study is to analyze the constitution, finding the association between obesity patients with obstructive sleep apnea and their related molecular typing and Traditional Chinese Medicine constitution.
Patients with HER2 positive breast cancer received treatment with oxaliplatin 130 mg/m2 IV day 1 and trastuzumab 6 mg/kg (following 8 mg/kg loading dose during cycle 1). Cycles were repeated every 21 days.
Patients receive AVD chemotherapy comprising doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
PURPOSE:To obtain a semisolid food containing new low-calorie Eucommia ulmoides comprising leaves of Eucommia ulmoides having no fear of diarrhea like cow's milk as a calcium source by adding leaves of Eucommia ulmoides or an extracted solution of leaves of Eucommia ulmoides to a food. CONSTITUTION:An Eucommia ulmoides-containing semisolid food comprising leaves of Eucommia ulmoides or an extracted solution of leaves of Eucomia ulmoides. The semisolid food is preferably prepared by blending leaves of Eucommia ulmoides or an extracted solution of leaves of Eucommia ulmoides with pectin. The leaves of Eucommia ulmoides are obtained by natural drying or various forced drying, or the leaves are powdered. The extracted solution of leaves of Eucommia ulmoides is obtained by extracting dried or ground leaves of Eucommia ulmoides with an extracting solvent such as water. After the extraction, the extracted solution may be optionally concentrated and decolored.
Stroke therapy had entered a new era since endovascular therapy was introduced in addition to intravenous thrombolysis. The benefit of endovascular therapy for patients with a proven proximal intracranial arterial occlusion has recently been revealed in several large randomized controlled trials. However, a substantial number of patients treated with reperfusion therapy did not reach functional independence in long-term follow-up, despite relatively high recanalization rates. Therefore, simple and more reliable markers that identify patients most likely to benefit from reperfusion therapy are needed. Accumulated studies showed that arterial status such as arterial collaterals had been considered as a critical predictor of outcome or determinant criteria for therapeutic selection. However, other evidences denied that arterial collaterals serve as a predictors for outcome after recanalization. Moreover, non-reflow phenomenon, over-reperfusion and futile recanalization may lead to large infarct, brain swelling, hemorrhagic complication and neurological deterioration. The traditional pathophysiological understanding on ischemic stroke can hardly explain these occurrences. Recently, the importance of cerebral venous drainage, the major blood reservoir and drainage system in brain, has been described for stroke evolution and clinical sequelae. In this study, the aim is to investigate the roles of cerebral venous dynamic status on neurological outcome after reperfusion therapy and the potential mechanisms behind poor veins and adverse outcome. In this study, the investigators will prospectively recruit the AIS patients over 18 years old who undergo baseline CTP/MRP and receive reperfusion therapy within 24 hour after onset. Each of their perfusion imaging will be reconstructed to evaluate the status of cerebral vein system. The investigators hypothesized that the venous dynamic status may have effect on the ischemic-reperfusion progress, and may thus has the potential to impact the stroke outcome. This study may add new implications for stroke outcome prediction and future therapeutic decision-making.
This is an open-label study (participants and the study physician \[Investigator\] will know the identity of the assigned treatments) to compare the pharmacokinetics (PK) (how the drugs are absorbed in the body) and pharmacodynamics (PD) (the actions or effects of drugs on the body) of rivaroxaban in study participants with mild or moderate renal impairment (reduced kidney function) receiving multiple doses of erythromycin, to the PK and PD of a single dose of rivaroxaban administered alone in study participants with normal renal function. The study drugs used will be rivaroxaban, a drug that acts to thin the blood to prevent the formation of blood clots, and erythromycin, an antibiotic used to treat patients with bacterial infections. Study participants with normal renal function will receive Treatment A (1 oral \[by mouth\] dose 10 mg rivaroxaban for 1 day) and Treatment C (500 mg oral erythromycin 3x a day (t.i.d.) on Days 1-6 + 1 oral dose of 10 mg rivaroxaban on Day 5). Study participants with mild and moderate renal impairment will receive Treatment A, Treatment B (500 mg oral erythromycin t.i.d. on Days 1-6 + 1 oral dose of 5 mg rivaroxaban Day 5), and Treatment C. Treatments A, B, and C will be separated by up to 14 days.
Epi proColon is blood based screening test for colorectal cancer that is FDA - PMA approved. It is indicated for average risk patients who are unwilling or unable to be screened with other recommended screening tests, including colonoscopy or fecal occult blood tests.

The PERT study is designed to assess the test performance of Epi proColon when it is used annually for two consecutive years. Subjects enrolled in the study will be offered initial testing. Subjects with a positive result will be referred for colonoscopy. Subjects with a negative test result will be encouraged to be screened the following year. At the one year interval, test negative subjects will be reminded to be rescreened. Subjects with a positive test will be referred for colonoscopy, while subjects with a negative test will be be encouraged to participate in a screening program in subsequent years.
INTRODUCTION: The Video Head Impulse Test (vHIT) is a safe and reliable assessment of peripheral vestibular function. Many studies tested its accuracy in clinical settings for differential diagnosis and quantification of the vestibulo-oculomotor reflex (VOR) in various disorders. However, the results of its application after lesions of the CNS are discordant and have never been studied in rehabilitation. This study aims to assess the VOR performance in a sample of stroke survivors.
METHODS: This is a cross-sectional study on 36 subacute and chronic stroke survivors; only persons with first-ever stroke and able to walk independently, even with supervision, were included. We performed VOR assessments for each semicircular canal by vHIT and balance assessments by the Berg Balance Scale and the MiniBESTest scale.
RESULTS: Two hundred and sixteen semicircular canals were assessed using the Head Impulse paradigm (in both the vertical and horizontal planes), while 72 semicircular canals were assessed using the Suppressed Head Impulse paradigm (horizontal plane). There was a high prevalence of participants with dysfunctional canals, particularly for the left anterior and right posterior canals, which were each prevalent in more than one-third of our sample. Furthermore, 16 persons showed an isolated canal dysfunction. The mean VOR gain for the vertical canals had confidence intervals out of the normal values (0.74-0.91 right anterior; 0.74-0.82 right posterior; 0.73-0.87 left anterior).
CONCLUSION: Our findings suggest that peripheral vestibular function may be impaired in people with stroke; a systematic assessment in a rehabilitation setting could allow a more personalized and patient-centred approach.
The present invention belongs to the technical field of pharmaceuticals, and particularly relates to a green and healthy medicine composition for preventing and treating inflammatory bowel disease. The medicine composition comprises: 15-25 g of roots of Codonopsis pilosula (Franch.) Nannf., 5-15 g of Atractylodes macrocephala Koidz., 15-25 g of Poria cocos (Schw.) Wolf, 1-10 g of Cornus officinalis Sieb. et Zucc., 1-10 g of Coptis chinensis Franch., 1-10 g of Curcuma Longa L., 5-15 g of Paederia scandens (Lour.) Merr., 5-15 g of Bletilla striata (Thunb.) Reichb.f., and 1-10 g of Glycyrrhiza uralensis Fisch. The solution disclosed by the present application has significant beneficial effect on the prevention and treatment of inflammatory bowel disease, and the herbs used in the present application are widely used traditional Chinese medicine products with no or low toxic effect; therefore, the green and healthy medicine composition has green, healthy and safe technical advantages.
The invention relates to temperature control slow release injection for bird immune globulin as well as a preparation method and an application thereof and belongs to the technical field of biological products. The temperature control slow release injection comprises the following components by weight percent: 0.5-5% of chiston, 2-20% of PEG (polyethylene glycol)6000, 2-20% of dipotassium phosphate, 0.1-2% of acid and the balance of water. The preparation method of the temperature control slow release injection comprises the steps of dissolving chiston in an aqueous solution containing acid, adding PEG 6000 and stirring until the PEG 6000 is dissolved, then adding a dipotassium phosphate aqueous solution, and uniformly stirring, thus the temperature control slow release injection is obtained. The invention also provides an application of the temperature control slow release injection in preparation of temperature control slow release injection of bird immune globulin. The temperature control slow release injection provided by the invention can delay release of bird immune globulin and can prolong time for absorbing immune globulin by an organism. The preparation method of the temperature control slow release injection is simple, operation is easy, no precise instrument is adopted, cost is low, and the temperature control slow release injection is easy to use.
FIELD: medicine. SUBSTANCE: method involves administering chrome tripicolinate in combination with biotin. Both preparations are administered per os or parenterally at such daily doses that gives 50 to 1000 mcg of chrome and 25 to 200 mg of biotin. Chrome and biotin are selected in proportions ensuring efficiency that is greater than additive effect. EFFECT: enhanced effectiveness of treatment. 10 cl
Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered concentrated (1:20 weight per volume \[w/v\]) daily doses of glycerinated German cockroach allergenic extract (50% glycerin) placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The extract was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
The standard-risk AML patients (18-60 years) receiving HLA-identical allogeneic stem cell transplantation in Peking University Institute of Hematology will be enrolled in this study if their MRD were positive before SCT, in CR1/CR2, remain in CR and MRD negative in the first two months after transplantation. The patients in this study will be treated with interferon-alpha injection twice a week (3 million units / time, iH) since the third month posttransplant. If the patients were well tolerated, the interferon-alpha treatment will continue 6 months. All the enrolled patients will undergo MRD monitoring after SCT as the same as the routine procedure. Bone marrow examination will be performed at the regular time points (+1, 2,3, 4, 5, 6, 9, 12 month) and 8-colour flow cytometry and RQ-PCR-based WT1 examination will be empolyed to evaluate MRD and disease status. Based on the statistical calculation, in order to reduce the incidence of relapse from 40% (previous data) to 15% (the cumulative incidence of relapse in pre-MRD- AML patients), total 29 patients will be enrolled. The main side effects might related to interferon-alpha include induction of severe GVHD, hematological toxicity and Flu - like symptoms. If the patients met the following criteria, they will withdraw from the trial: 1）met the combined criteria for positive MRD (MRDco+) which was defined as 2 consecutive FCM+ or WT1+ results or both FCM+ and WT1+ in a single sample within 1 year after transplantation; 2）hematological relapse; 3) grade III or IV acute GVHD, or moderate/ severe chronic GVHD; 4) severe infection; 5) grade IV hematological toxicity; 6) organ failure; 7) death; 8) patients refuse to continue the interferon-alpha treatment. The main end point of the study is one-year cumulative incidence of relapse. the second end points include OS, NRM, DFS, MRD, GVHD, infection and hematological toxicity.
For oral health education intervention via Meta-OHE, it will be done via computer in a computer lab. The participants will be gathered in their school's computer lab with the health of the teacher. Participants will be assigned a computer to each of them. Then, they will be asked to sign in into Mitoworld platform using their respective email address on https://mitoworld.io/world/w/2808/meta-ohe to access Meta-OHE. They will be asked to enter the Meta-OHE portal. The students are permitted to freely explore and follow the instruction to visit each section of the Meta OHE and interact with each other. They will also be assigned a few tasks for them to complete on the platform to ensure all the oral health education materials are being covered. The duration of the session will be around 60-90 minutes. Pre-assessment will be taken prior to their access to Meta-OHE. Post assessment will be taken afterwards to assess the oral health knowledge, practise and attitude.
The quasi-experimental unblinded interrupted time-series (ITS) design will be conducted in three phases: pre-intervention/ (10 weeks); during intervention (16 weeks); post-intervention (20 weeks). A cohort of patients on selected wards will receive the BE-FIT program intervention.
The recipe of the present invention consists of rhizome of davallia, raw alibanum, raw myrrh, raw sichuan aconite root, raw wild aconite root, raw rhizoma Arisaematis, notoptery-gium, pubescent angelica root, honeylocust fruit and Chinese prickly ash etc. traditional Chinese medicinal herbs which are made into external application prepn. through the processes of mixing, crushing, sieving and packing with cloth. Said product functions tonifying the kidney, reinforcing the bone, promoting the circulation of blood and removing blood stasis, detumescence, stopping pain, and expelling cold by warming the channel, treating the disease by looking into both its root cause and symptoms. Especially for treating hyperostosis. It features good curative effect, small stimulation, strong permeability, no toxic side effects, the total effective rate comes up to 95.40%.
All participants receive a 12-week lifestyle intervention (diet and exercise). The intervention group was monitored initial 1-week with a RT-CGM.
PCT No. PCT/EP91/00208 Sec. 371 Date Jul. 30, 1992 Sec. 102(e) Date Jul. 30, 1992 PCT Filed Jan. 30, 1991 PCT Pub. No. WO91/11105 PCT Pub. Date Aug. 8, 1991Anti-microbial compositions are described which contain iodide and thiocyanate anions, an oxidoreductase enzyme, namely glucose oxidase, and its corresponding oxidisable substrate, D-glucose. Such compositions may advantageously further comprise a peroxidase such as lactoperoxidase. The compositions have excellent anti-microbial properties effective against bacteria yeasts and moulds. The compositions may be provided in concentrated substantially non-reacting forms such as dry powders and non-aqueous solutions which may be diluted to provide compositions with broad spectrum anti-microbial activity. Compositions may be used as preservatives or as active agents providing potent anti-microbial activity of use in oral hygiene, deodorant and anti-dandruff products.
Stroke is the leading cause of adult disability in the United States. Approximately one-third of all strokes result in acute language impairment (aphasia), with approximately one-fifth suffering from chronic aphasia. Unfortunately, the prognosis for moderate to severe chronic aphasia remains grim, as current behavioral treatment approaches usually offer only limited-to-modest benefit. Recent advancements in understanding the relationship between low current electrical brain stimulation and cortical plasticity suggest that the effect of behavioral aphasia treatment could possibly be enhanced using anodal transcranial direct current stimulation (A-tDCS). Indeed, we have shown how A-tDCS can significantly boost the effect of behavioral aphasia treatment. Based on these results as well as our other studies aimed at understanding how favorable brain plasticity correlates with positive treatment outcome in aphasia, we propose to conduct a Phase II clinical trial utilizing a futility design. Consistent with the goals of Program Announcement PAR-08-204 by the National Institute on Deafness and Other Communication Disorders (NIDCD), we plan to "evaluate whether there is sufficient evidence of short term improvement in humans to justify a phase III trial."
The invention discloses an application method of a natural peptide in the preparation of Kv4.2 potassium channel tool reagents. This bioactive peptide is SPKP-X. Experiments show that this peptide has evident prohibitory action on voltage-gated potassium channel subtype Kv4.2 channels. In the preparation of the voltage-gated potassium channel subtype tool reagents, the concentration of an extracellularly administered drug to be prepared is 100nmol/L or 500nmol/L. The median effective dose IC50 of the SPKP-X is 68nmol/L. The prohibition of the SPKP-X upon Kv4.2 channels is time dependent and reversible, and the SPKP-X is a good Kv4.2 potassium channel tool reagent.